Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
•
Medical Oncology
•
Breast Cancer, Metastatic
Are you comfortable combining palliative radiotherapy with capivasertib/fulvestrant?
Any pitfalls to be aware of?
Answer from: Medical Oncologist at Community Practice
Yes. Follow CBC
Sign In
or
Register
to read more
22945
Related Questions
What are your top takeaways in Radiation Oncology from SABCS 2024?
What are your top takeaways in Medical Oncology from SABCS 2024?
What are your top takeaways in Breast Cancer from ESMO 2025?
What are your top takeaways in Breast Cancer from ASCO 2025?
What factors should be considered when deciding between datopotamab deruxtecan and sacituzumab govitecan for a patient with metastatic breast cancer?
How would you approach the treatment of low grade, stage IA, triple negative apocrine adenocarcinoma of the breast in a female patient in her 70s?
In a patient with metastatic PIK3CA-mutant, HR-positive, HER2-low breast cancer who is intolerant to capivasertib, would you preferentially use another PIK3 inhibitor or switch to T-DXd?
Is there any benefit of anastrozole in addition to fulvestrant and palbociclib in a patient with HR+ metastatic breast cancer?
Do you recommend using a ctDNA assay for a patient with HER2+ metastatic breast cancer in a continued CR to guide decision about whether to stop anti therapy?
Does pre-chemotherapy extent of nodal involvement impact your decision to offer adjuvant radiation in cN1, ypN0 triple-negative breast cancer?